Cílem výzvy je podpořit personalizovanou léčbu rakoviny a snížit její dopad prostřednictvím výzkumu a iniciativ, jako je Evropský plán boje proti rakovině.
Typ žadatele: Konsorcia
Předpokládaný rozpočet projektu: 3 mil. €
Objective:
The aim of the action is to complement the implementation of the ‘Joint Action on Personalized Cancer Medicine’ led by the Member States, thus helping to reduce the burden of cancer both at a personal and societal level, namely by supporting the Europe’s Beating Cancer Plan and policy initiatives on personalised medicine. It may also support other Union initiatives that aim at improving public health, such as the ‘1+ Million Genomes’ Initiative and the Initiative to Understand Cancer (UNCAN.eu) in so far as it shares the objectives of promoting personalised treatments and support ground-breaking research needed to advance the understanding of cancer mechanisms in order to improve the cancer care pathway.
Scope:
Activities will contribute to the Joint Action on Personalized Cancer Medicine’, and include:
- the implementation of targeted projects involving civil society organisations and industry complementing the Member States’ efforts in the design, planning and implementation of best practices (e.g., on metastatic cancer);
- the production of public health guidelines concerning personalised cancer medicine, genomic testing/screening and metastatic cancer management;
- patients and caregivers consultations, and other actions that can benefit citizens directly;
- preparation and roll out of innovative practices;
- support capacity building actions such as training and twinning, health communication or health literacy.
Expected Impact:
The action will benefit cancer patients accessing personalised cancer medicine services, which is expected to reduce the burden of cancer in the Member States.
The expected results will include initiatives to complement the Member States’ efforts in the design, planning and implementation of best practices, such as support for the development of public health guidelines (e.g., personalised cancer medicine, genomic testing/screening and metastatic cancer management) guidelines and, support for the preparation and roll out of new policy approaches; participation in the pilot testing of innovative practices; development of capacity building actions such as training and twinning, health communication or health literacy.
The actions that will complement the Joint Action on Personalized Cancer Medicine are expected to bring short-term improvements in implementing personalised cancer medicine and sharing best practice among Member States and countries associated to the EU4Health Programme. In the mid- to long- term, this is expected to improve innovation and patient management in the cancer pathway, including metastatic cancer, by improving knowledge and skills in implementing personalised medicine in oncology.